PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $423,660 | -26.1% | 13,809 | -3.5% | 0.01% | -14.3% |
Q2 2023 | $573,362 | -4.5% | 14,309 | -2.7% | 0.01% | 0.0% |
Q1 2023 | $600,274 | +2.0% | 14,709 | -3.5% | 0.01% | -12.5% |
Q4 2022 | $588,764 | -27.3% | 15,249 | +0.2% | 0.01% | -33.3% |
Q3 2022 | $810,000 | -6.9% | 15,220 | +2.0% | 0.01% | -7.7% |
Q2 2022 | $870,000 | -32.6% | 14,920 | -11.8% | 0.01% | 0.0% |
Q1 2022 | $1,291,000 | +26.8% | 16,913 | 0.0% | 0.01% | +18.2% |
Q4 2021 | $1,018,000 | +2.6% | 16,913 | -4.5% | 0.01% | 0.0% |
Q3 2021 | $992,000 | -8.2% | 17,713 | -0.6% | 0.01% | -8.3% |
Q2 2021 | $1,081,000 | -13.5% | 17,813 | 0.0% | 0.01% | -20.0% |
Q1 2021 | $1,249,000 | +21.0% | 17,813 | +3.3% | 0.02% | +7.1% |
Q4 2020 | $1,032,000 | -0.8% | 17,241 | -0.3% | 0.01% | -6.7% |
Q3 2020 | $1,040,000 | +16.6% | 17,300 | +1.8% | 0.02% | +15.4% |
Q2 2020 | $892,000 | +56.5% | 17,000 | 0.0% | 0.01% | +30.0% |
Q1 2020 | $570,000 | -26.0% | 17,000 | 0.0% | 0.01% | -9.1% |
Q4 2019 | $770,000 | – | 17,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |